Literature DB >> 9188586

Adenovirus vector-infected cells can escape adenovirus antigen-specific cytotoxic T-lymphocyte killing in vivo.

S C Wadsworth1, H Zhou, A E Smith, J M Kaplan.   

Abstract

The recent findings that prolonged expression of certain adenovirus (Ad) vector-encoded proteins, including human alpha1-antitrypsin (huAAT), mouse erythropoietin (EPO), and human factor IX, can be achieved in animals that do not mount an immune response to the reporter protein were obtained with mouse strains which have been shown to be capable of mounting a cellular immune response against Ad vector antigens. This suggests either that Ad vectors expressing nonimmunogenic transgenes fail to elicit a cellular immune response or that an Ad-specific cellular immune response does develop but is ineffective against cells expressing nonimmunogenic transgenes. Here we demonstrate that an Ad vector expressing huAAT administered by intravenous injection does stimulate an Ad-specific cellular immune response but that this response fails to abolish vector-directed gene expression in vivo. Moreover, expression of huAAT remained stable in animals stimulated by concurrent and multiple administrations of different Ad vectors or viruses. We also demonstrate prolonged expression of huAAT in CD1 mice transgenic for the huAAT gene, indicating that long-term expression is not restricted to C57BL/6 mice. These results demonstrate that under some circumstances, an Ad vector can direct prolonged expression of a nonimmunogenic transgene despite the presence of a robust Ad-specific cellular immune response.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9188586      PMCID: PMC191754          DOI: 10.1128/JVI.71.7.5189-5196.1997

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  25 in total

1.  Specificities of killing by cytotoxic lymphocytes generated in vivo and in vitro to syngeneic SV40 transformed cells.

Authors:  L R Gooding
Journal:  J Immunol       Date:  1977-03       Impact factor: 5.422

2.  Selective expansion of high- or low-avidity cytotoxic T lymphocytes and efficacy for adoptive immunotherapy.

Authors:  M A Alexander-Miller; G R Leggatt; J A Berzofsky
Journal:  Proc Natl Acad Sci U S A       Date:  1996-04-30       Impact factor: 11.205

3.  Development of a complementing cell line and a system for construction of adenovirus vectors with E1 and E2a deleted.

Authors:  H Zhou; W O'Neal; N Morral; A L Beaudet
Journal:  J Virol       Date:  1996-10       Impact factor: 5.103

4.  The constitutive expression of the immunomodulatory gp19k protein in E1-, E3- adenoviral vectors strongly reduces the host cytotoxic T cell response against the vector.

Authors:  M G Lee; M A Abina; H Haddada; M Perricaudet
Journal:  Gene Ther       Date:  1995-06       Impact factor: 5.250

5.  Stabilization of transgene expression by incorporation of E3 region genes into an adenoviral factor IX vector and by transient anti-CD4 treatment of the host.

Authors:  W Poller; S Schneider-Rasp; U Liebert; F Merklein; P Thalheimer; A Haack; R Schwaab; C Schmitt; H H Brackmann
Journal:  Gene Ther       Date:  1996-06       Impact factor: 5.250

6.  Effective treatment of familial hypercholesterolaemia in the mouse model using adenovirus-mediated transfer of the VLDL receptor gene.

Authors:  K F Kozarsky; K Jooss; M Donahee; J F Strauss; J M Wilson
Journal:  Nat Genet       Date:  1996-05       Impact factor: 38.330

7.  Characterization of factors involved in modulating persistence of transgene expression from recombinant adenovirus in the mouse lung.

Authors:  J M Kaplan; D Armentano; T E Sparer; S G Wynn; P A Peterson; S C Wadsworth; K K Couture; S E Pennington; J A St George; L R Gooding; A E Smith
Journal:  Hum Gene Ther       Date:  1997-01-01       Impact factor: 5.695

8.  Strain related variations in adenovirally mediated transgene expression from mouse hepatocytes in vivo: comparisons between immunocompetent and immunodeficient inbred strains.

Authors:  D Barr; J Tubb; D Ferguson; A Scaria; A Lieber; C Wilson; J Perkins; M A Kay
Journal:  Gene Ther       Date:  1995-03       Impact factor: 5.250

9.  Sustained expression of therapeutic levels of human factor VIII in mice.

Authors:  S Connelly; J M Gardner; R M Lyons; A McClelland; M Kaleko
Journal:  Blood       Date:  1996-06-01       Impact factor: 22.113

10.  Immune responses to transgene-encoded proteins limit the stability of gene expression after injection of replication-defective adenovirus vectors.

Authors:  S K Tripathy; H B Black; E Goldwasser; J M Leiden
Journal:  Nat Med       Date:  1996-05       Impact factor: 53.440

View more
  13 in total

1.  Implication of interfering antibody formation and apoptosis as two different mechanisms leading to variable duration of adenovirus-mediated transgene expression in immune-competent mice.

Authors:  D B Schowalter; C L Himeda; B L Winther; C B Wilson; M A Kay
Journal:  J Virol       Date:  1999-06       Impact factor: 5.103

Review 2.  Nonneurotropic adenovirus: a vector for gene transfer to the brain and gene therapy of neurological disorders.

Authors:  Pedro R Lowenstein; Donata Suwelack; Jinwei Hu; Xianpeng Yuan; Maximiliano Jimenez-Dalmaroni; Shyam Goverdhana; Maria G Castro
Journal:  Int Rev Neurobiol       Date:  2003       Impact factor: 3.230

3.  One-year expression from high-capacity adenoviral vectors in the brains of animals with pre-existing anti-adenoviral immunity: clinical implications.

Authors:  Carlos Barcia; Maximiliano Jimenez-Dalmaroni; Kurt M Kroeger; Mariana Puntel; Alison J Rapaport; Daniel Larocque; Gwendalyn D King; Stephen A Johnson; Chunyan Liu; Weidong Xiong; Marianela Candolfi; Sonali Mondkar; Philip Ng; Donna Palmer; Maria G Castro; Pedro R Lowenstein
Journal:  Mol Ther       Date:  2007-09-25       Impact factor: 11.454

Review 4.  Message therapy: gene therapy that targets mRNA sequence and stability.

Authors:  K F Kozarsky; L A Couture
Journal:  Am J Hum Genet       Date:  1997-10       Impact factor: 11.025

5.  Administration of helper-dependent adenoviral vectors and sequential delivery of different vector serotype for long-term liver-directed gene transfer in baboons.

Authors:  N Morral; W O'Neal; K Rice; M Leland; J Kaplan; P A Piedra; H Zhou; R J Parks; R Velji; E Aguilar-Córdova; S Wadsworth; F L Graham; S Kochanek; K D Carey; A L Beaudet
Journal:  Proc Natl Acad Sci U S A       Date:  1999-10-26       Impact factor: 11.205

6.  In vitro and in vivo biology of recombinant adenovirus vectors with E1, E1/E2A, or E1/E4 deleted.

Authors:  M Lusky; M Christ; K Rittner; A Dieterle; D Dreyer; B Mourot; H Schultz; F Stoeckel; A Pavirani; M Mehtali
Journal:  J Virol       Date:  1998-03       Impact factor: 5.103

7.  Systemic and central nervous system correction of lysosomal storage in mucopolysaccharidosis type VII mice.

Authors:  C S Stein; A Ghodsi; T Derksen; B L Davidson
Journal:  J Virol       Date:  1999-04       Impact factor: 5.103

8.  Virus-induced hepatocellular carcinomas cause antigen-specific local tolerance.

Authors:  Gerald Willimsky; Karin Schmidt; Christoph Loddenkemper; Johanna Gellermann; Thomas Blankenstein
Journal:  J Clin Invest       Date:  2013-02-01       Impact factor: 14.808

9.  Adenovirus-mediated persistent cystic fibrosis transmembrane conductance regulator expression in mouse airway epithelium.

Authors:  A Scaria; J A St George; C Jiang; J M Kaplan; S C Wadsworth; R J Gregory
Journal:  J Virol       Date:  1998-09       Impact factor: 5.103

Review 10.  Adenovirus as a carrier for the development of influenza virus-free avian influenza vaccines.

Authors:  De-chu C Tang; Jianfeng Zhang; Haroldo Toro; Zhongkai Shi; Kent R Van Kampen
Journal:  Expert Rev Vaccines       Date:  2009-04       Impact factor: 5.217

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.